Dimension Inx, a company that develops biomaterials for 3D printing, has signed a distribution agreement with Advanced Solutions Life Sciences (ASLS), a company specializing in biofabrication technologies. Through the partnership, ASLS will now offer Dimension Inx’s bioprinting materials to clients around the globe.
Dimension Inx’s materials are part of its proprietary 3D-Painting platform, and can be used for a range of hard and soft tissue biofabrication applications. The company’s materials include Hyperelastic Bone and 3D-Graphene, among others.
By adding the 3D-Paints portfolio to ASLS’ platform, the biofabrication company is aiming to create new possibilities for its clients in the research, clinical and industrial healthcare sectors. With access to more biomaterials, ASLS customers can seek to advance the development of 3D printed complex biological tissue structures.
“We are extremely excited to begin this partnership with ASLS and work with them to provide their customers significantly more biomaterial options and solutions for their customer’s tissue and organ engineering needs,” commented Dr. Ramille Shah, Chief Science Officer and co-founder of Dimension Inx.
As per the distribution agreement, ASLS will offer Dimension Inx’s Hyperelastic Bone, 3D-Graphene and 3D-Graphite materials immediately. Down the line, the companies say ASLS will expand its material offering.
Michael Golway, CEO of ASLS, said of the collaboration: “I’m a big fan of Dr. Ramille Shah and her scientific focus to advance the biofabrication industry. I’m delighted our customers will be able to gain access to her and her team’s innovations through this agreement.”
Dr. Shah and Dr. Adam E. Jakus co-founded Chicago-based Dimension Inx in 2017 for the purpose of developing highly advanced 3D printable biomaterials. The young company has already made quite an impact on the bioprinting industry, having partnered with Allevi Inc. and Advanced BioMatrix. Dimension Inx’s 3D-Paints are already being used to address major clinical challenges and are helping to improve patient care.
ASLS, for its part, is known best for its patented BioAssemblyBot and BioBot technology platform. The company also develops and offers a software platform as well as professional services and supplies.
In addition to the distribution agreement between them, the two companies are also both members of the Advanced Regenerative Manufacturing Institute (ARMI|BioFabUSA), a public-private organization whose goal is to accelerate the development and adoption of large-scale manufacturing for engineered tissues and tissue-related technologies.
